Catapult Ventures led the seed round alongside Neo Kuma Ventures, Wren Capital, and o2H ventures to support the Cambridge Cognition spinout.
"By establishing Monument Therapeutics, we have created an exciting new venture to develop stratified medicine in CNS drug development that could help many patients with unmet clinical needs. It leverages Cambridge Cognition’s intellectual property and provides the potential for considerable royalty payments in the future, while the Company continues to focus on the development and commercialisation of its cutting-edge digital health technologies."
The financing round was led by Oxford Sciences Innovation to support the company in expanding its peptide discovery operations.
"Orbit’s team has the right combination of scientific rigor and novel peptide technologies to lead a new generation of drug development, and we look forward to partnering with the team to advance their mission,"
The funding round was led by Praetura Ventures with participation from the Development Bank of Wales and Perscitus.
"It’s been a landmark year for Reacta, and we continue to go from strength-to-strength as a business, developing new diagnostic products and expanding our capabilities. The number of people experiencing food allergies is increasing, so it’s vital that technologies to accurately and safely test for allergies are developed. We’re committed to providing excellence in the development of a suite of OFC products, and revolutionising the way food allergies are diagnosed worldwide."
The seed round was backed by ACF Investors, o2h Ventures, and angel investors to fund team expansion and platform development.
"With this investment, our investors have affirmed the strength of our technology and its commercial potential. Building upon years of research, this funding will drive the development of our platform, facilitate the rollout of our own range of therapeutics and expand our team. As our recent collaboration with the UCL Drug Discovery Institute has shown, we are beginning to have a potent effect on the pharmaceutical industry and I am looking forward to the many ways in which we can make a decisive contribution to medicine worldwide"
